Low titer on a bispecific isn’t a dead end. It’s where most partners stop looking.
Complex modalities tend to fail quietly — a low titer here, an aggregation problem there — until they surface as months of rework late in development. Conjugation chemistry, DAR control, multi-chain expression: these are exactly the problems that separate a CDMO from a true development partner.
Bring us the molecule everyone else called “challenging.”
We hear “challenging” and we hear “this is our lane.” High-performance CHO cell lines, deep analytical muscle, and a CMC strategy that surfaces problems early — so your complex molecule gets a clean path to GMP.
- Bispecifics & multi-specifics. Expression and manufacturability strategies built for multi-chain formats.
- T-cell engagers. Analytical depth for potency, stability, and aggregation risk.
- Conjugation chemistry, DAR control, and characterization held together end to end.
- Fusion proteins. Manufacturability designed in from the start, not patched in later.
A technical playbook, not a sales deck.
Our whitepaper breaks down how we lift expression and manufacturability on complex modalities — with real strategies for bispecific and multi-specific formats. Then join the companion webinar with the scientists who wrote it.
An ADC is only as strong as its most fragile step.
Conjugation chemistry, DAR control, aggregation, analytical characterization — an antibody-drug conjugate stacks hard problems on top of an already-complex protein. Our ADC capability brief breaks down how we hold yield, purity, and consistency across the steps where ADC programs most often slip.
